In particular, it might be useful to incorporate additional prognostic markers such as L1CAM, CTNNB1, and ARID1A (10, 26, 40–42), and at the same time explore the impact in risk assessment by rare histotypes of aggressive carcinoma (e.g., mesonephric, neuroendocrine, gastric-type carcinomas) currently not included in present guidelines (43). This evidence concerns the gene CTNNB1 and carcinoma.